Novartis: China is becoming the global launch market for the company's breakthrough therapies.

On November 6, Novartis showcased the innovative immunology investigational drug Ianalumab for the first time at the 9th China International Import Expo, presenting Novartis's research progress in the field of Sjgren's syndrome through a "China debut." Gao Rong, Head of Novartis Pharmaceuticals Development China, stated that the CIIE provides an excellent platform for the company to showcase global innovation achievements, and China is becoming a global launch market for Novartis's breakthrough therapies.